UK-based contract research organisation (CRO) Chiltern has completed the integration of its early-phase units in Slough and Dundee, after snapping up the Scottish facility in February through the acquisition of Phase I specialist Drug Development Solutions (DDS).

Operating under the Chiltern Early Phase brand, the integrated units offer a total of 72 high-care beds, 42 of them based at the Ninewells Hospital in Dundee. Chiltern Early Phase can cover all therapeutic areas and types of clinical pharmacology study, with particular expertise in first-in-human, drug photosensitivity, drug-drug-interaction, Japanese bridging and vaccine trials, the CRO says.

According to Dr Brian Sanderson, former chief executive officer (CEO) of DDS and now medical director of Chiltern Early Phase, the division is looking to expand its operations in Slough and Dundee, both in areas of traditional strength and new specialisations such as diabetes and cardiovascular medicine. It also wants to forge academic links to provide specialist studies involving biomarkers.

“When we created Chiltern Early Phase, our vision was to develop a brand that would be synonymous with quality and service excellence,” commented Chiltern’s CEO, Glenn Kerkhof. “We now have the team, organisation and facilities to deliver on this vision and provide a truly expert early-phase service at reasonable cost.”